ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,247.79
-0.41%
Dow Jones
39,112.16
-0.76%
Gold vs US Dollar
2,320.55
-0.44%
Brent Oil
84.185
-1.27%
Bitcoin
61,722.73
2.42%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nexalin Technologies Inc (NXLIW)

  7. Nexalin Technologies Inc (NXLIW) News

Nexalin Technologies (NXLIW)

Nexalin Technologies Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NXLIW
DateTimeSourceHeadlineSymbolCompany
20/06/202413:30GlobeNewswire Inc.Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and DementiaNASDAQ:NXLIWNexalin Technologies Inc
18/06/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXLIWNexalin Technologies Inc
14/06/202414:53Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:NXLIWNexalin Technologies Inc
13/06/202420:00GlobeNewswire Inc.Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)NASDAQ:NXLIWNexalin Technologies Inc
12/06/202418:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXLIWNexalin Technologies Inc
04/06/202413:30GlobeNewswire Inc.Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6thNASDAQ:NXLIWNexalin Technologies Inc
03/06/202413:30GlobeNewswire Inc.FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset DeviceNASDAQ:NXLIWNexalin Technologies Inc
23/05/202422:17Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:NXLIWNexalin Technologies Inc
22/05/202413:30GlobeNewswire Inc.Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research EffortsNASDAQ:NXLIWNexalin Technologies Inc
21/05/202421:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXLIWNexalin Technologies Inc
14/05/202421:54Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:NXLIWNexalin Technologies Inc
10/05/202419:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXLIWNexalin Technologies Inc
09/05/202413:30GlobeNewswire Inc.Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23NASDAQ:NXLIWNexalin Technologies Inc
25/04/202415:44GlobeNewswire Inc.Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:NXLIWNexalin Technologies Inc
09/04/202413:30GlobeNewswire Inc.Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical TestingNASDAQ:NXLIWNexalin Technologies Inc
04/04/202418:00GlobeNewswire Inc.Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceNASDAQ:NXLIWNexalin Technologies Inc
02/04/202413:30GlobeNewswire Inc.Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory BoardNASDAQ:NXLIWNexalin Technologies Inc
28/03/202412:30GlobeNewswire Inc.Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San DiegoNASDAQ:NXLIWNexalin Technologies Inc
14/03/202412:30GlobeNewswire Inc.Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s TechnologyNASDAQ:NXLIWNexalin Technologies Inc
13/03/202412:30GlobeNewswire Inc.Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”NASDAQ:NXLIWNexalin Technologies Inc
08/02/202413:30GlobeNewswire Inc.Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation DeviceNASDAQ:NXLIWNexalin Technologies Inc
23/01/202413:30GlobeNewswire Inc.Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) SystemNASDAQ:NXLIWNexalin Technologies Inc
11/01/202413:30GlobeNewswire Inc.Nexalin Technology Unveils Next-Generation HALO™ ClarityNASDAQ:NXLIWNexalin Technologies Inc
18/12/202313:30GlobeNewswire Inc.Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant DepressionNASDAQ:NXLIWNexalin Technologies Inc
25/10/202313:30GlobeNewswire Inc.Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David LasseterNASDAQ:NXLIWNexalin Technologies Inc
16/10/202313:30GlobeNewswire Inc.Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain StructuresNASDAQ:NXLIWNexalin Technologies Inc
07/08/202313:30GlobeNewswire Inc.Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related SymptomsNASDAQ:NXLIWNexalin Technologies Inc
03/08/202313:30GlobeNewswire Inc.Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern TimeNASDAQ:NXLIWNexalin Technologies Inc
26/07/202313:30GlobeNewswire Inc.Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government AgenciesNASDAQ:NXLIWNexalin Technologies Inc
10/07/202313:30GlobeNewswire Inc.Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain InjuryNASDAQ:NXLIWNexalin Technologies Inc
 Showing the most relevant articles for your search:NASDAQ:NXLIW

Your Recent History

TG
CRS1
Ercros
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved